Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Tepezza Lumvoa Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.03.93

    Lumvoa and Tepezza for thyroid eye disease

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.03.93 alerts

    Get alerted when Policy 05.03.93 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw) to treat thyroid eye disease. Coverage applies when product-specific clinical, specialist-prescriber, documentation, and treatment-history requirements are met, subject to the member's benefit contract.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyLumvoa and Tepezza for thyroid eye disease
    Policy CodePolicy 05.03.93
    Change TypeNo material change
    Effective DateSeptember 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with clinical records documenting the applicable thyroid eye disease criteria, clinical activity or proptosis findings, disease severity, and thyroid testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered products
    18+Minimum member age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Initial approval duration
    1 lifetimeMaximum course
    8 infusionsTepezza lifetime limit
    5 infusionsLumvoa lifetime limit

    Coverage Criteria

    Tepezza initial therapy

    Tepezza is medically necessary when ALL of the following are met.

    Tepezza initial approval

    • Member is 18 years of age or older.
    • ONE of the following TED pathways

      • Member has active thyroid eye disease with a clinical activity score (CAS) ≥4.CAS ≥4
      • Member has moderate-to-severe chronic thyroid eye disease with either a ≥3 mm increase in proptosis from baseline before the thyroid eye disease diagnosis or proptosis ≥3 mm above normal values for race and sex.≥3 mm increase from baseline or ≥3 mm above normal values for race and sex
    • Member has moderate-to-severe disease.
    • ONE of the following glucocorticoid or current-treatment pathways

      • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose, unless the member has documented intolerance, an FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
      • Member is currently receiving Tepezza through insurance, excluding treatment obtained as samples or through a manufacturer's patient assistance program, and is experiencing a positive therapeutic outcome.
    • Member is euthyroid before initiating therapy.
    • Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
    • Member has not received prior treatment with another insulin-like growth factor inhibitor, including Lumvoa, for thyroid eye disease.

    Lumvoa initial therapy

    Lumvoa is medically necessary when ALL of the following are met.

    Lumvoa initial approval

    • Member is 18 years of age or older.
    • ONE of the following TED pathways

      • Member has active thyroid eye disease with a clinical activity score (CAS) ≥3.CAS ≥3
      • Member has moderate-to-severe chronic thyroid eye disease with proptosis ≥17 mm at the time of request and proptosis ≥3 mm above normal values for race and sex.Proptosis ≥17 mm at request and ≥3 mm above normal values for race and sex
    • Member has moderate-to-severe disease.

    Prior treatment with the other insulin-like growth factor inhibitor for thyroid eye disease precludes approval. A Tepezza request is not approved when the member has previously received Lumvoa for thyroid eye disease, and a Lumvoa request is not approved when the member has previously received Tepezza for thyroid eye disease.

    Pregnancy precludes approval. The member must not be currently pregnant and must not plan to become pregnant during treatment or within 6 months after the last treatment.

    Coding and Clinical Thresholds

    Procedures and billing codesHCPCS
    C9061Injection, teprotumumab-trbw, 10 mg (deleted 0930-2020)
    J3241Injection, teprotumumab-trbw, 10 mg (effective 10-01-2020)
    J3590Unclassified biologics (when specified as Lumvoa [veligrotug])
    J3490Unclassified drugs (when specified as Lumvoa [veligrotug])
    C9399Unclassified drugs/biologics (when specified as Lumvoa [veligrotug])
    Tepezza Active Thyroid Eye Disease
    ProductTepezza (teprotumumab-trbw)
    Active disease thresholdClinical activity score (CAS) ≥ 4
    Covered disease pathwayActive thyroid eye disease with CAS ≥ 4
    Lumvoa Active Thyroid Eye Disease
    ProductLumvoa (veligrotug)
    Active disease thresholdClinical activity score (CAS) ≥ 3
    Covered disease pathwayActive thyroid eye disease with CAS ≥ 3

    Provider Requirements and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required to initiate coverage review for Lumvoa or Tepezza. Submit supporting clinical records demonstrating that the applicable product-specific coverage criteria are met and that no therapy exclusions apply.

    • Include documentation supporting the diagnosis of thyroid eye disease and all applicable approval criteria.
    Step Therapy

    Glucocorticoid Prerequisite

    Before approval, the member must have had an inadequate response to glucocorticoids at a maximally tolerated dose. An exception applies when there is documented intolerance, an FDA-labeled contraindication, or hypersensitivity; coverage may also continue when the member is receiving the requested product through insurance and has a positive therapeutic outcome.

    • Do not count samples or manufacturer patient assistance programs as qualifying insurance treatment.
    • Document the applicable prerequisite or exception in the clinical record.

    Thyroid Eye Disease Background

    Thyroid eye disease (TED) is an ocular manifestation associated with thyroid disease. It may cause inflammatory activity, proptosis, soft-tissue involvement, and diplopia; severe disease may lead to optic neuropathy or corneal breakdown.

    Clinical Definitions

    Clinical Activity Score (CAS)
    Pain behind the globePainful feeling behind the globe over the last 4 weeks
    Pain with eye movementPain with eye movement during the last 4 weeks
    Eyelid rednessRedness of the eyelids
    Conjunctival rednessRedness of the conjunctiva
    Eyelid swellingSwelling of the eyelids
    ChemosisEdema of the conjunctiva
    Swollen caruncleSwollen caruncle, the flesh body at the medial angle of the eye

    Initial Therapy Criteria

    Tepezza initial therapy

    Tepezza may be considered medically necessary for thyroid eye disease when ALL of the following are met.

    Tepezza

    • Member is 18 years of age or older.
    • ONE of the following TED pathways

      • Member has active thyroid eye disease with a clinical activity score (CAS) ≥4.CAS ≥4
      • Member has moderate-to-severe chronic thyroid eye disease with either a ≥3 mm increase in proptosis from baseline before the thyroid eye disease diagnosis or proptosis ≥3 mm above normal values for race and sex.≥3 mm increase from baseline or ≥3 mm above normal values for race and sex

    Step Therapy Requirements

    StepRequirementDocumented exceptions
    1Try glucocorticoids at a maximally tolerated dose before the requested product. An inadequate response is required before initial therapy.Intolerance, an FDA-labeled contraindication, or hypersensitivity to glucocorticoids.

    Lifetime Quantity Limits

    Tepezza Quantity Limit
    ProductTepezza
    Maximum course quantityUp to 8 infusions
    Lifetime limitOne course of treatment per lifetime
    Lumvoa Quantity Limit
    ProductLumvoa
    Maximum course quantityUp to 5 infusions
    Lifetime limitOne course of treatment per lifetime
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyLumvoa and Tepezza for thyroid eye disease
    Policy CodePolicy 05.03.93
    Change TypeNo material change
    Effective DateSeptember 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with clinical records documenting the applicable thyroid eye disease criteria, clinical activity or proptosis findings, disease severity, and thyroid testing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Coverage RisksThyroid Eye Disease BackgroundClinical DefinitionsInitial Therapy CriteriaStep Therapy RequirementsLifetime Quantity Limits
  1. ONE of the following glucocorticoid or current-treatment pathways

    • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose, unless the member has documented intolerance, an FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
    • Member is currently receiving Lumvoa through insurance, excluding treatment obtained as samples or through a manufacturer's patient assistance program, and is experiencing a positive therapeutic outcome.
  2. Member is euthyroid before initiating therapy.
  3. Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
  4. Member has not received prior treatment with another insulin-like growth factor inhibitor, including Tepezza, for thyroid eye disease.
  5. Tepezza Chronic Thyroid Eye Disease
    Disease typeModerate-to-severe chronic thyroid eye disease
    Baseline comparisonAt least a 3 mm increase in proptosis from baseline before thyroid eye disease diagnosis
    Alternative thresholdProptosis at least 3 mm above normal values for race and sex
    Lumvoa Chronic Thyroid Eye Disease
    Disease typeModerate-to-severe chronic thyroid eye disease
    Proptosis at requestProptosis ≥ 17 mm at the time of request
    Race-and-sex comparisonProptosis ≥ 3 mm above normal values for race and sex
    Moderate-to-Severe Disease: Proptosis
    FindingExophthalmos
    Threshold≥ 3 mm above normal
    Reference standardNormal values for race and gender
    Moderate-to-Severe Disease: Lid Retraction
    FindingLid retraction
    Threshold≥ 2 mm
    Disease categoryModerate-to-severe thyroid eye disease
    Documentation Required

    Required Clinical Records

    Submit chart notes or medical records documenting the clinical findings needed for review, including disease activity, proptosis when applicable, disease severity, and thyroid status.

    • Clinical activity score (CAS): >= 4 for Tepezza active disease or >= 3 for Lumvoa active disease.
    • Proptosis testing when applicable: Tepezza chronic disease requires either a >= 3 mm increase from baseline or >= 3 mm above normal for race and sex; Lumvoa requires proptosis >= 17 mm and >= 3 mm above normal for race and sex.
    • Moderate-to-severe thyroid eye disease and thyroid testing results, including euthyroid status before treatment.

    Unsupported block type: info

    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when the member does not satisfy the product-specific medical-necessity criteria. Review must establish the required age, thyroid eye disease diagnosis, activity or proptosis findings, disease severity, treatment history, and other applicable clinical conditions.

    • Member must be 18 years of age or older and have moderate-to-severe thyroid eye disease.
    • Tepezza: active disease with CAS >= 4, or moderate-to-severe chronic disease with the required proptosis change or elevation.
    • Lumvoa: active disease with CAS >= 3, or moderate-to-severe chronic disease with proptosis >= 17 mm and >= 3 mm above normal for race and sex.
    • Member must be euthyroid before initiating therapy and must not be pregnant or plan pregnancy during treatment or within 6 months after the last treatment.
    • Member must meet the glucocorticoid prerequisite or a documented exception and must not have received another insulin-like growth factor inhibitor for thyroid eye disease.
    Denial Risk

    Lifetime Course Limit

    Approval is limited to 6 months and one course of treatment per lifetime. Requests exceeding the lifetime course limit or the product-specific infusion limit may be denied.

    • Tepezza: up to 8 infusions per lifetime.
    • Lumvoa: up to 5 infusions per lifetime.
    Documentation Required

    Documentation and Specialist Involvement

    Incomplete records or lack of required specialist involvement can delay, suspend, or prevent completion of the prior authorization review and may result in denial.

    • Ensure the submission includes CAS, applicable proptosis measurements, moderate-to-severe disease documentation, thyroid testing results, treatment history, and the specialist prescriber or consultation record.
    • Records should clearly identify whether the request is for Lumvoa or Tepezza and demonstrate the corresponding product-specific criteria.
    Moderate-to-Severe Thyroid Eye Disease
    Lid retractionLid retraction ≥ 2 mm
    Soft-tissue involvementModerate or severe soft-tissue involvement
    ExophthalmosExophthalmos ≥ 3 mm above normal for race and gender
    DiplopiaInconstant or constant diplopia
    Sight-Threatening Disease
    ConditionSight-threatening thyroid eye disease
    Optic nerve findingDysthyroid optic neuropathy (DON)
    Corneal findingCorneal breakdown
  6. Member has moderate-to-severe disease.
  7. ONE of the following glucocorticoid or current-treatment pathways

    • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose, unless the member has documented intolerance, an FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
    • Member is currently receiving Tepezza through insurance, excluding treatment obtained as samples or through a manufacturer's patient assistance program, and is experiencing a positive therapeutic outcome.
  8. Member is euthyroid before initiating therapy.
  9. Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
  10. Member has not received prior treatment with another insulin-like growth factor inhibitor, including Lumvoa, for thyroid eye disease.
  11. Lumvoa initial therapy

    Lumvoa may be considered medically necessary for thyroid eye disease when ALL of the following are met.

    Lumvoa

    • Member is 18 years of age or older.
    • ONE of the following TED pathways

      • Member has active thyroid eye disease with a clinical activity score (CAS) ≥3.CAS ≥3
      • Member has moderate-to-severe chronic thyroid eye disease with proptosis ≥17 mm at the time of request and proptosis ≥3 mm above normal values for race and sex.Proptosis ≥17 mm at request and ≥3 mm above normal values for race and sex
    • Member has moderate-to-severe disease.
    • ONE of the following glucocorticoid or current-treatment pathways

      • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose, unless the member has documented intolerance, an FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
      • Member is currently receiving Lumvoa through insurance, excluding treatment obtained as samples or through a manufacturer's patient assistance program, and is experiencing a positive therapeutic outcome.
    • Member is euthyroid before initiating therapy.
    • Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
    • Member has not received prior treatment with another insulin-like growth factor inhibitor, including Tepezza, for thyroid eye disease.